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Abstract
Background: Cisplatin-based treatment has been considered the standard treatment regimen of HNSCC. Cetuximab is
an emerging target therapy that has potential therapeutic benefits over cisplatin. Nevertheless, curative effects of
cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) are still controversial.
Methods: Potentially eligible studies were retrieved using PubMed, Embase and Medline. Basic characteristics of
patients and statistical data were collected. A meta-analysis model was established to compare CRT and BRT.
Results: Thirty-one eligible studies and 4212 patients were found. The pooled HRs with 95 % confidence intervals (CIs)
for OS and PFS were 0.32 [0.09, 0.55] and 0.51 [0.22, 0.80], respectively, and both were in favor of cisplatin. However,
3-year survival and recurrence analysis of the subgroups showed no differences between the two groups (p > 0.05).
In subgroup analysis, oropharyngeal primary tumors exhibited improved results by cetuximab with a pooled HR of 1.56
[1.14, 2.13] for PFS. Additionally, the HPV+ status was a significant factor in positive outcomes with cetuximab with a
pooled HR of 1.12 [0.46, 2.17] for OS.
Conclusion: Long-term use of BRT showed no significant difference compared with CRT, and both arms showed
different aspects of toxicity. In subgroup analysis, taking the effects of treatment and adverse events into consideration,
cetuximab plus radiation may show superior responses regarding OS and PFS in patients who have HPV+ or primary
oropharyngeal HNSCC, respectively, but physicians should administer them with caution.
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Background
Squamous cell carcinoma of the head and neck (HNSCC)
consists of cancers arising from the oral cavity, pharynx
and larynx and comprises approximately 5 % of all cancers
worldwide. The global incidence is increasing by half a
million and causing more than 350,000 deaths every year
[1, 2]. A limited number of patients with locally advanced
disease are suitable for potentially curative surgery or
definitive radiotherapy. Patients who are not candi-
dates for surgery or definitive radiotherapy may receive
chemotherapy plus radiation or systemic chemotherapy
alone [3].
Cisplatin-based chemoradiotherapy is now considered
to be the established standard, first-line chemotherapy
to treat patients with locally advanced HNSCC [69].
Many large randomized studies and meta-analyses have
demonstrated that cisplatin-based concurrent chemora-
diotherapy regimens provide significantly higher response
rates than radiotherapy alone [4, 5].
Epidermal growth factor receptor (EGFR) seems to be
critical to cancer cell growth and proliferation, and the
function of EGFR in these two settings appears to be
different [6, 7]. Head and neck cancer cells exhibit this
difference compared to normal cells without exception
[8]. In addition, EGFR expression was markedly
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increased or over-expressed in HNSCC compared to
normal tissue, which has been shown to be an independ-
ent prognostic factor for poor survival [9]. Thus, EGFR
inhibitors have become a burgeoning strategy in anti-
tumor treatment. To date, several monoclonal antibodies
targeting EGFR have been successfully used in clinical
practice with significant effects. Improved loco-regional
control and prolonged survival time have already been
achieved in lung and gastro-intestinal cancers [10–12].
Cetuximab, an EGFR-targeting monoclonal antibody,
is the first targeted therapy to show therapeutic benefit
in head and neck cancer [13] and received FDA approval
for use in treating HNSCC in 2006 [14, 15]. The Bonner
trial showed impressively increased survival outcomes
and loco-regional control rates when comparing cetuximab
plus radiation versus radiation alone [16]. The Merlano
trial exhibited a promising treatment response from adding
cetuximab to standard chemotherapy, with limited toxicity
[17]. Clinical trials have shown that the addition of cetuxi-
mab to traditional treatment regimens (e.g., cisplatin plus
radiation) could improve survival outcomes [18, 19].
However, this combination may lead to increased
treatment-related toxicity and increased cost, and the ad-
ministration of multiple drugs may worsen quality of life.
Hence, we conducted a meta-analysis with the aims of
gathering outcomes from clinical trials and obtaining a
larger sample size to compare the curative effects
between the administration of cisplatin-based chemora-
diotherapy (CRT) or cetuximab-based bioradiotherapy
(BRT) with regards to survival results, loco-regional con-
trol or distant metastasis (failure), and treatment-related
adverse effects in patients with HNSCC.
Methods
Search strategy
PubMed, Embase and Medline were searched on Mar
13, 2016. The following keywords were used to retrieve
articles and abstracts: head and neck squamous cell
carcinoma (HNSCC), cancers of larynx, cancers of oral
tongue, cancers of oropharynx, cancers of laryngopharynx,
cetuximab, cisplatin and radiotherapy.
Study selection and inclusion/exclusion criteria
Titles and abstracts were reviewed in all of the searched
studies, and full texts were reviewed in potentially
eligible studies according to our inclusion criteria. To
avoid duplicated data, when more than one trial was
completed with crossed data in a single center, only the
largest most updated trials were included.
In our meta-analysis, we used the following inclusion
criteria: (1) studies containing patients with locally
advanced HNSCC, including the following: cancers of
the larynx, cancers of the oral tongue, cancers of the
oropharynx, or cancers of the laryngopharynx; (2)
studies comparing the administration of cisplatin-based
chemotherapy versus cetuximab-based biotherapy; and
(3) studies with available data regarding survival out-
comes of patients included in the clinical trials. On the
other hand, studies were excluded based on the follow-
ing criteria: (1) articles that consisted of in vitro studies
or were review articles; (2) studies with duplicated data,
meaning that one analysis that had several articles
reporting updated outcomes; and (3) studies containing
metastatic and/or recurrent disease.
Data extraction
The following two investigators reviewed all of the
articles independently: Huang JW and Shi CL. Any
discrepancy was discussed until reaching a consensus.
The data were independently extracted from eligible
studies by two investigators (Huang JW and Shi CL),
and then, the obtained data were integrated. The pri-
mary data consisted of HRs with a 95 % confidence
interval (CI) or event/total patient numbers regarding
survival outcomes, including OS and/or PFS and the
recurrence rates, such as loco-regional and/or distant
recurrence of disease in patients from cetuximab cohorts
and cisplatin cohorts.
The additional data obtained from the studies included
the first author, publication year, patient source (region),
median age, percentage of each sex, TNM stage at
diagnosis, treatment regimens, tumor site (%), survival
outcomes, recurrence rates, type of study, toxicity N
(G3 ~ 4) in CRT vs. BRT groups, and attitude of the ori-
ginal studies. The statistical data for acquiring logHR
and SE were also obtained, including HR with a 95 % CI,
Kaplan–Meier survival curves with p values, and re-
sponse rates of the over-expression cohort compared to
the normal/lower expression cohort [20].
Statistical methods
logHR and SE were required in our analysis. Some of
the original papers provided logHR and SE directly,
whereas other studies did not. As mentioned above, we
utilized other data to calculate these values using methods
developed by Parmar et al. (1998) [21], Williamson et al.
(2002) [22], and Tierney et al. (2007) [23]. The logHRs
and SEs were calculated with the methods described
earlier when 1) there was a HR with 95 % CI or 2) there
was a p value for the log-rank test with the Kaplan–Meier
survival curve.
Hazard ratio (HR) was used as the measure index to
describe the survival outcomes and disease control rates
between the BRT arm and CRT arm (we considered the
cisplatin regimen as the standard regimen). As a result
of the analysis of survival in patients, a significant out-
come was defined by a p value < 0.05, while a p value >
0.05 indicated no significant difference between the two
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comparison arms. Pooled HRs > 1 combined with p < 0.05
indicate a narrow difference between the two groups, and
the cetuximab arm showed higher event incidences. In
contrast, pooled HRs < 1 indicated a lower incidence of
events in the cetuximab cohort. Furthermore, pooled
HRs > 2 or <0.5 denote a significant result. We use the
term “positive” to indicate a better outcome related to
cetuximab treatment and “negative” to indicate an absence
of correlation between the two comparison arms or better
outcomes in the cisplatin arm.
In terms of heterogeneity, values of p < 0.10 or I2 >
50 % represent heterogeneity existing in the pooled HRs
(Higgins et al., 2003) [24]. When homogeneity was
minimal (p ≥ 0.10, I2 ≤ 50 %), a fixed-effects model was
applied for secondary analysis; otherwise, a random-
effects model was used. All of the earlier calculations
and publication bias were measured using the Begg’s
funnel plot, which was performed by STATA 11.0
(STATA Corporation, College Station, TX). This calcula-
tion for the current meta-analysis was performed using
REVIEW MANAGER (version 5.0 for Windows; the
Cochrane collaboration, Oxford, UK).
The sensitive analysis, which aims to test for the
heterogeneity of all of the included studies and to
determine if heterogeneity arose from any single study,
was performed by STATA 11.0 (STATA Corporation,
College Station, TX). In the analytic figure, an absence
of heterogeneity is indicated by the containment of the
studies within the constricted interval (defined between
lower CI limit and Upper CI limit), while the existence
of a single study far outside the confidence interval indi-




We initially obtained 794 studies from PubMed, Embase
and Medline. After reviewing these abstracts, 73 poten-
tially relevant studies were identified as candidates for a
full-text review. We excluded 42 studies for the follow-
ing reasons: twenty-one were clinical trials focused on
CRT vs. CRT plus cetuximab, four were reviews, three
were posters without follow-up statistics on the studies,
and seven were in vitro studies (Fig. 1).
Finally, we enrolled 31 eligible articles containing
survival outcomes [25–50]. These eligible studies were
published from 2008 to 2016 and included a total of
4212 patients, ranging from 24 to 421 patients per study
(median, 126). The basic clinical characteristics of pa-
tients and other useful information are shown in
Table 1.
Comparison between cisplatin-based and cetuximab
regarding overall survival
Twenty-three settings of accommodated data showed
patients’ overall survival (OS). In these trials, patients
were scheduled to receive cisplatin-based chemotherapy
plus radiation or cetuximab single agent plus radiation.
The pooled HRs to compare OS between the two groups
showed better outcomes with cisplatin-based therapy
and the mathematic value is 0.32 [0.09, 0.55], p = 0.006
(Table 2; Fig. 2).
Subgroup analysis
As survival outcomes were largely influenced by time of
observation, we categorized OS outcomes by year of
estimation: 2-years, 3-years, or 5-years and beyond. The
Fig. 1 Selection of Studies
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Table 1 Basic characteristics of included studies
Author Type of study Region Age Stage Female (%) Therapy regimens HPV statue (+) Survival
Cisplatin Cetuximab Cisplatin Cetuximab Cisplatin Cetuximab
Vermorken JB RS America CRT: 57.8 BRT: 57 Stage III/IV NR RT-CIS VS. RT-CET NR 2-yrOS 1-yr PFS





L.D. Koutcher RS America NR RT-CIS VS. RT-CET 16 (42 %) 8 (35 %) 30-mon PFS
30-mon OS




Koutcher L RS America CRT: 56 BRT: 66 Stage III/IV CRT:17 (13.6 %) BRT:11 (22.5 %) RT-CIS VS. RT-CET NR 2-yr FFS
2-yr OS
2-yr LRC







CRT Adjuvant: 36 CET Adjuvant: 36
Ley J RS America CRT: 55 BRT: 62 Stage III/IV CRT: 16.7 BRT: 34.5 RT-CIS VS. RT-CET NR 3-yr DSS
3-yr LRR
Ye AY RS Canada CRT: 57 BRT: 62 Stage III/IV CRT: 17 BRT: 14 RT-CIS VS. RT-CET NR 3-yr OS
3-yr DFS
3-yr LRC




Stage III/IV p16 Negative:7 p16 Positive: 6 RT-CIS VS. RT-CET 10 (18 %) 8 (15 %) 2-yr OS
2-yr DFS
2-yr LRR
Lefebvre JL Phase II RCT France CRT: 57.5 BRT: 57.8 Stage II-IV CRT: 13.3 BRT: 1.7 RT-CIS VS. RT-CET NR 18-mon OS
18-mon LRR
36-mon OS
M. Ghi RCT Italy 60 Stage III/IV 80.5 CCRT VS. Cet+RT NR 3-yr OS
3-yr PFS
N. Riaz RCT America NR NR NR CCRT VS. Cet+RT 24 (56%) 11 (75%) NR


















Table 1 Basic characteristics of included studies (Continued)



























RS America 53 NR NR RT-CIS VS. RT-CET NR LRC
3-yr OS
2-yr PFS
Riaz N RS America NR NR NR RT-CIS VS. RT-CET NR NR
Riaz N RS America NR Stage III/IV CRT: 21 BRT: 22 RT-CIS VS. RT-CET 31 (86 %) 17 (74 %) NR




S.L.Galper RS America CRT: 58 BRT: 71 NR NR RT-CIS VS. RT-CET NR NR
D.Borchiellini RS France CRT: 56 BRT: 57 NR CRT 16 % BRT 8 % RT-CIS VS. RT-CET NR NR
Lorraine Walsh RS Ireland CRT: 57.5 BRT: 63 Stage III/IV CRT : 9 % BRT : 11.8 % RT-CIS VS. RT-CET NR NR
Stefano Maria
Magrini
RCT America CRT: 67.5 BRT: 61 Stage III/IV CRT: 31 % BRT:26 % RT-CIS VS. RT-CET NR 2-yr OS
Tobin J. Strom RS America CRT: 58 BRT: 62 Stage III/IV CRT: 16.2 BRT: 5.3 RT-CIS VS. RT-CET 43.4 % 41.2 % 2-yrOS






NR CRT : 21 % BRT: 22 % RT-CIS VS. RT-CET 86 74 3-yr LRC 3-yr OS
3-yr PFS
CRT cisplatin-based chemoradiotherapy, BRT cetuximab-based bioradiotherapy, RT-CIS radiation plus cisplatin, RT-CET radiation plus cetuximab, CCRT concurrent chemoradiotherapy, yr year, mon month, HPV Human
papillomavirus, RS retrospective study, RCT randomized controlled study, OS overall survival, PFS progression free survival, L-PFS local progression free survival, D-PFS distant progression free survival, FFS failure-free
survival, LRR locoregional recurrence, DFS disease free survival, DSS disease specific survival, LRC locoregional control, RFS relapse-free survival, DM distant metastasis, EFS event-free survival, CCS cause-specific survival,












pooled HR for 2-year estimation was 0.44 [0.13, 0.76],
p = 0.006, which supports better survival achieved with
cisplatin-based therapy, while the 3-year or 5-year and be-
yond time assessments showed no significant difference
between the two groups, with pooled HRs of 0.21 [-0.14,
0.55], p = 0.241and 0.95 [0.51, 1.74], p = 0.86, respectively
(Table 2; Fig. 2).
Human papillomavirus (HPV) infection state might
contribute to pathogenesis of HNSCC, and it has previ-
ously been demonstrated that HPV positive (HPV+)
cases showed better prognosis and prolonged survival in
the cetuximab single agent group. The pooled HR is
1.12 [0.46, 2.17], p = 0.015 (Table 2; Fig. 3).
The oropharynx was shown to be distinct in prognosis
and therapy response compared with HNSCC in other
locations. On this account, we analyzed this group
separately, and the results showed that patients with
primary tumors in the oropharynx exhibited similar values
of OS with a pooled HR of 0.13 [-0.03, 0.89], p = 0.743
(Table 2; Fig. 4).
Comparison between cisplatin-based and cetuximab
therapies regarding progression-free survival
Twenty-one studies published data including progression
free survival (PFS). The PFS results displayed a similar
tendency as the OS and the mathematic value for the
pooled HR was 0.51 [0.22, 0.80], p = 0.001 (Table 2; Fig. 5).
Subgroup analysis
As assessed in the OS data, we categorized PFS outcomes
by time intervals of estimation: 2-years, or 3-years and be-
yond. The pooled HRs were 0.56 [0.20, 0.92], p = 0.002,
Table 2 Pooled HRs (95 % Cl) comparing survival outcomes and recurrence between BRT & CRT
Comparison Survival outcome Study N. Model HR (95 % Cl) P value Heterogeneity (p ,I2) Conclusion
BRT vs. CRT OS 23 Random 0.32 [0.09, 0.55] 0.006 P < 0.00001; I² = 84.6 % Positive
BRT vs. CRT OS for 2-yr 11 Random 0.44 [0.13, 0.76] 0.006 P < 0.0001; I² = 76.9 % Positive
BRT vs. CRT OS for 3-yr 12 Random 0.21 [-0.14, 0.55] 0.241 P < 0.00001; I² = 88.8 % Negative
BRT vs. CRT PFS 21 Random 0.51 [0.22, 0.80] 0.001 P < 0.00001; I² = 90.1 % Positive
BRT vs. CRT PFS for 2-yr 10 Random 0.56 [0.20, 0.92] 0.002 P < 0.00001; I² = 88.2 % Positive
BRT vs. CRT PFS for 3-yr 11 Random 0.45 [-0.05, 0.95] 0.076 P < 0.00001; I² = 91.8 % Negative
BRT vs. CRT Locoregional control 19 Random 0.49 [0.14, 0.85] 0.007 P < 0.00001; I² = 91 % Positive
BRT vs. CRT Locoregional control for 2-yr 9 Random 0.63 [0.09, 1.17] 0.023 P < 0.00001; I² = 83 % Positive
BRT vs. CRT Locoregional control for 3-yr 10 Random 0.06 [-0.40, 0.52] 0.808 P < 0.00001; I² = 93.3 % Negative
BRT vs. CRT Distant control 5 Random 0.25 [0-0.06, 0.56] 0.118 P < 0.00001; I² = 88.3 % Negative
BRT vs. CRT OS for oropharynx 7 Random 0.13 [-0.03, 0.89] 0.743 P < 0.00001; I² = 84.8 % Negative
BRT vs. CRT PFS for oropharynx 3 Random 1.56 [1.14, 2.13] 0.006 P < 0.00001; I² = 96 % Positive
BRT vs. CRT Locoregional control for oropharynx 6 Random 1.75 [0.6, 5.26] 0.31 P < 0.00001; I² = 89.1 % Negative
BRT vs. CRT OS for HPV+ 5 Fixed 1.12 [0.46, 2.17] 0.015 P = 0.22; I² = 38 % Positive
BRT vs. CRT PFS for HPV+ 5 Random 0.80 [0.38, 1.67] 0.55 P < 0.00001; I² = 92 % Negative
BRT vs. CRT Locoregional control for HPV+ 5 Random 1.17 [0.69, 2.00] 0.56 P = 0.01; I² = 71.1 % Negative
CRT cisplatin-based chemoradiotherapy, BRT cetuximab-based bioradiotherapy, N number, OS overall survival, PFS progression-free survival, CI confidence interval,
HR hazard ratio, yr year
Fig. 2 Meta-analysis estimated OS comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of estimation
of 2-yr OS; (b) subgroup of estimation of 3-yr OS. OS, overall survival
Huang et al. BMC Cancer  (2016) 16:689 Page 6 of 16
and 0.45 [-0.05, 0.95], p = 0.076 for the 2-year and 3-years
and beyond time assessments, respectively, which indicate
that better survival was achieved with cisplatin-based
therapy (Table 2; Fig. 5).
For the HPV+ group, cetuximab-based therapy again
showed outcomes superior to those of cisplatin-based
therapy, and the pooled HR was 0.80 [0.38, 1.67], p = 0.55
(Table 2; Fig. 3).
We also analyzed PFS separately in patients with
oropharynx tumors, and those patients who received
cetuximab-based regimens showed prolonged PFS com-
pared with administration of cisplatin-based therapy; the
pooled HR was 1.56 [1.14, 2.13], p = 0.006 (Table 2; Fig. 4).
Comparison between cisplatin-based and cetuximab
therapies regarding loco-regional containment
Nineteen studies reported loco-regional control or loco-
regional failure in patients with HNSCC. The pooled HR
to compare OS between the two groups showed better
outcomes with cisplatin-based therapy, and the mathe-
matic value was 0.49 [0.14, 0.85], p = 0.007 (Table 2;
Fig. 6).
Subgroup analysis
Loco-regional control, like other recurrence rates and
survival outcomes, directly correlated to the estimated
time interval, and thus, we categorized the loco-regional
control rates by the year of estimation: 2-years, 3-years,
or 5-years and beyond. The pooled HR for the 2-year es-
timation was 0.63 [0.09, 1.17], p = 0.023, which supports
better survival achieved with cisplatin-based therapy,
while the 3-years or 5-years and beyond time assess-
ments showed no significant difference between the two
groups, and the pooled HRs were 0.34 [-0.12, 0.79],
p = 0.15 and 2.67 [0.47, 8.73], p = 0.27, respectively
(Table 2; Fig. 6).
Patients with HPV+ infection states showed a non-
significantly better prognosis and prolonged survival in
the cetuximab single agent group, and the pooled HR
was 0.06 [-0.40, 0.52], p = 0.808 (Table 2; Fig. 3).
Analysis of patients with primary tumors in the
oropharynx showed no significant difference between
the cisplatin and cetuximab groups with a pooled HR
of -0.05 [-1.34, 0.35], p = 0.248 (Table 2; Fig. 4).
Comparison between cisplatin-based and cetuximab
therapies regarding distant metastasis
Five studies reported incidences of distant metastases.
The pooled HR was 0.25 [0-0.06, 0.56], p = 0.118,
indicating no significant difference between cisplatin and
cetuximab administration (Table 2; Fig. 7).
Fig. 3 Meta-analysis compared cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy in estimating patients in HPV+ subgroup
regarding to OS, PFS, and LRC. OS, overall survival; PFS, progression-free survival; LRC, locoregional control
Fig. 4 Meta-analysis compared cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy in estimating patients with oropharyngeal
primary tumor regarding to OS, PFS and LRC. OS, overall survival; PFS, progression-free survival; LRC, locoregional control
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Assessment of adverse events
Twenty-one types of acute toxicity or late toxicity in pa-
tients treated with cisplatin plus radiotherapy or cetuxi-
mab plus radiotherapy were assessed. The pooled HRs of
all toxicities, including acute and late toxicities, showed
no difference for patients who received cisplatin-based or
cetuximab-based therapy, and the mathematic value was
-0.34 [-0.72, 0.04], p = 0.079 (Fig. 8).
Subgroup analysis
We estimated individual toxicities separately, which is
shown in Fig. 9. We found that incidence of toxicities, such
as leukopenia (p = 0.00), acute kidney injury (p = 0.002),
and neutropenia (p = 0.002), were significantly higher in
the cisplatin plus radiotherapy regimen, while some
dermatitis-related toxicities, such as acneiform rash
(p = 0.002), displayed a higher incidence in the cetuximab
plus radiotherapy regimen. Other toxicities showed no
statistical significance between the two groups (Table 3;
Fig. 9).
Results from sensitive tests
As shown in Fig. 10, all of the scattered points were
restricted within the interval of the lower CI and upper
CI limitations, which indicated that the heterogeneity
was acceptable and constrained (Fig. 10).
Assessment of publication bias
On the basis of Begg’s funnel plot, the p value was
greater than 0.10, which indicates that the publication
bias was acceptable in the analysis. According to Begg’s
funnel plot analysis, the publication bias arising in the
OS cohort (p = 0.758), the PFS cohort (p = 0.90), the
loco-regional control cohort (p = 0.83) or the distant
metastasis cohort (p = 0.854) was acceptable (Fig. 11).
Discussion
In this systemic review, we conducted a meta-analysis to
compare the effect of cisplatin-based chemotherapy plus
radiotherapy versus cetuximab plus radiotherapy in con-
trolling the overall survival, progression-free survival,
loco-regional recurrence and distant metastasis of locally
advanced HNSCC. Meanwhile, different time periods of
estimation, primary tumor sites in the oropharynx and
HPV infection status were also taken into consideration.
Our study demonstrated that in all settings of the esti-
mated OS time duration, the outcomes were found to be
better with cisplatin treatment; however, specifically
observing the longer follow-up time intervals, patients
between the two groups shared similar overall survival
rates, as there was no statistical significance between the
two groups with a follow-up time duration equal to or
longer than 3 years. Progression-free survival and loco-
regional control rates displayed similar tendencies as the
OS rates. In subgroup analysis, tumors with a primary
site in the oropharynx and tumors with HPV+ infection
status showed non significantly better PFS and OS,
respectively, with cetuximab single agent treatment plus
radiotherapy, while no remarkable difference was ob-
served between the remaining survival outcomes and
loco-regional control in the two subgroups, indicating
that equivalent effects of the two treatment regimens
were achieved in these categories.
Fig. 5 Meta-analysis estimated PFS comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of
estimation of 2-yr PFS; (b) subgroup of estimation of 3-yr PFS. PFS, progression-free survival
Huang et al. BMC Cancer  (2016) 16:689 Page 8 of 16
Fig. 6 Meta-analysis estimated LRC comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of
estimation of 2-yr LRC; (b) subgroup of estimation of 3-yr LRC. LRC, locoregional control
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Fig. 7 Meta-analysis estimated DM comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. DM, distant metastasis
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Fig. 8 Meta-analysis compared cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy in estimating toxicities including
acute and late toxicities
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Fig. 9 Meta-analysis compared cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy in estimating patients with oropharyngeal
primary tumor and with single toxicity separately
Table 3 Pooled HRs 95 % Cl for toxicity between CRT & BRT
Comparison Adverse event/ Toxicity Study N. Model HR 95 % [Cl] P value Heterogeneity (p ,I2) Conclusion
CRT vs. BRT Mucositis 7 Fixed 0.05 [-0.09, 0.19] p=0.493 P = 0.45; I² = 36.9 % Negative
CRT vs. BRT Dysphagia 5 Fixed -0.07 [-0.35, 0.21], p=0.63 P = 0.89; I² = 0 % Negative
CRT vs. BRT Xerostomia 2 Fixed 0.51 [0.09, 2.95], p=0.46 P = 0.17; I² = 46 % Negative
CRT vs. BRT Laryngeal edema 2 Fixed 0.91 [0.71, 1.18] p=0.49 P = 0.89; I² = 0 % Negative
CRT vs. BRT Acute kidney injury 5 Fixed -1.30 [-2.11, -0.49] p=0.002 P = 0.32; I² = 0 % Positive
CRT vs. BRT Nausea or vomiting 4 Random -1.30 [-2.66, 0.06], p=0.061 P = 0.03; I² = 57.2 % Negative
CRT vs. BRT Radiation dermatitis 4 Random 0.31 [-0.45, 1.08] p=0.419 P = 0.001; I² = 87.6 % Negative
CRT vs. BRT Acneiform rash 5 Random 3.49 [1.23, 5.74] P=0.002 P = 0.87; I² = 81 % Positive
CRT vs. BRT Neutropenia 3 Fixed -0.88 [-1.42, -0.33] p=0.002 P < 0.00001; I² = 0.0 % Positive
CRT vs. BRT Ototoxicity 3 Fixed 0.16 [0.04, 0.69] p=0.10 P = 0.60; I² = 0 % Negative
CRT vs. BRT Infectious 2 Fixed 3.31 [0.55, 19.87] p=0.19 P = 0.59; I² = 0 % Negative
CRT vs. BRT Neuropathy 2 Fixed 0.80 [0.46, 1.41] p=0.44 P = 0.37; I² = 0 % Negative
CRT vs. BRT Pain 2 Fixed 0.92 [0.80, 1.06] p=0.24 P = 0.74; I² = 0 % Negative
CRT vs. BRT Leukopenia 4 Fixed -0.76 [-1.16, -0.36] P=0.001 P = 0.19; I² = 44.2 % Positive
CRT vs. BRT Late toxicity 4 Fixed 1.11 [0.83, 1.47], p=0.48 P = 0.53; I² = 0 % Negative
CRT vs. BRT Total toxicity 21 Random -0.34 [-0.72, 0.04] P=0.079 P < 0.00001; I² = 91.7 % Negative
CRT cisplatin-based chemoradiotherapy, BRT cetuximab-based bioradiotherapy, N number, CI confidence interval, HR hazard ratio, CRT chemoradiothrapy,
BRT bioradiothrapy
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Fig. 10 Sensitive analysis evaluated heterogeneity of OS cohort, PFS cohort and related subgroups. (a) Evaluation in OS group: total, 2-yr and
3-yr. (b) Evaluation in PFS group: total, 2-yr, and 3-yr. OS, overall survival; PFS, progression-free survival
Fig. 11 Estimated Begg’s funnel plots of publication bias regarding OS, PFS, LRC, and DM cohort respectively. OS, overall survival; PFS, progression-free
survival; LRC, locoregional control; DM, distant metastasis
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Concurrent cisplatin-based therapy has been regarded
as the standard treatment regimen for patients with
HNSCC [51]; however, cisplatin has been reported to
cause immediate treatment-related adverse events and
delayed toxicity. Cetuximab, an emerging monoclonal
antibody therapeutic, targeting epidermal growth factor
receptor (EGFR), seemed promising to provide patients
with an effective alternative treatment [52]. Whether
cetuximab could replace cisplatin in definitive chemora-
diotherapy for HNSCC remains controversial because
cetuximab has a reasonably good toxicity profile [53] but
the tumor control effect and survival benefit present in-
consistent results.
Therefore, to achieve better quality of life and avoid
these aggressive treatment regimens, concurrent cetuxi-
mab plus radiation versus cisplatin plus radiation therap-
ies have been compared. A recent meta-analysis including
15 studies comparing CCRT and concurrent cetuximab
with radiotherapy, with various estimation time inter-
vals, suggested that cisplatin usage improved OS and
PFS [54], consistent with our results. Nevertheless, it
seems that these drug responses and effects will bene-
fit patients in certain circumstances. In our analysis,
we showed that patients from selected subgroups of
HNSCC might benefit from concurrent cetuximab
plus radiotherapy.
In our analysis, we found that both the oropharyngeal
primary tumor and HPV+ subgroups showed differences
regarding survival outcomes, possibly supporting the
utility of cetuximab to a large extent.
We focused on HPV+ patients, as the biological behav-
ior of these tumors showed particularity. HPV is now con-
sidered to be an independent and important risk factor in
HNSCC [55, 56]. Recently, Dayyani et al. published a
meta-analysis, which showed that HPV infection has a
critical impact on survival and response to therapy, and
they also demonstrated that HPV+ status was not rare
(HPV+ 22 %, with 86.7 % exhibiting HPV16+ genotype)
[57]. However, some negative outcomes also exist, and no
significant difference was shown between cisplatin and
cetuximab with radiation in LAHNC [58]. One major obs-
tacle in this work was the lack of information regarding
the HPV/p16 status; thus, we suggest that patients should
undergo HPV testing for this unique and separate biologic
entity. In our analysis, patients in the HPV+ group
achieved better OS due to the highly selective and biologic
characteristics, which made the HPV+ group more
suitable for the concurrent BRT treatment regimen than
the whole HNSCC group.
We also observed unique responses in patients who
had primary lesions in the oropharynx. One comprehen-
sive study estimated chemotherapy effects via tumor
sites, and the results showed increased benefits only for
oropharyngeal and laryngeal tumors [59, 60]. There are
well-established patient risk factors associated with HPV
infection in oropharyngeal cancer, and a higher
incidence of HPV infection was found in cancers of the
oropharynx [61, 62]. In our analysis, better PFS was
observed in the oropharyngeal group rather than all
cases of HNSCC, which could support the administra-
tion of cetuximab as a single agent plus radiation in this
specific subgroup.
Adverse effects are important additional parameters to
be taken into consideration when comparing treatment
regimens. In our analysis, we found that there were no sig-
nificant differences between the two groups for all toxicity
data. The cisplatin regimen resulted in adverse events, in-
cluding high-grade neutropenia, leukopenia and acute kid-
ney injury, while adverse events due to BRT included
grade 3-4 acne-like rash and oral mucositis. We found
that the incidence of adverse events was elevated in ad-
vanced cases. One recent study published by Lawrence D.
Koutcher et al, showed serious grade radiation dermatitis
with spontaneous bleeding in patients undergoing the
BRT regimen [63], which could further decrease quality of
life [64] and have a negative impact on cosmetic out-
comes [65]. As the total incidence of adverse events did
not show significance between cisplatin and cetuximab
and the two regimens cause different adverse events in
different aspects, doctors need to take toxicity into
consideration and choose regimens according to each
patient’s condition.
To further confirm the quantity of evidence of the an-
alyzed the data, heterogeneity and sensitive analysis were
examined, and no obvious heterogeneity was detected;
as shown in every group estimation, I2 was <50 %, with
no exception. In addition, the further sensitive analysis
assessed heterogeneity in detail and revealed only limited
heterogeneity. In addition, as this is a meta-analysis,
some limitations still exist. Primarily, only published
data from prospective or retrospective studies were in-
cluded in our meta-analysis, without individual data.
Therefore, we could only use these integrated data,
which may lead to patient selection bias as patient selec-
tion and reporting processes could not be controlled by
us. In addition, we combined both retrospective and
randomized trials in our meta-analysis, which could also
contribute to the bias of this meta-analysis as the inclu-
sion criteria of these two types of studies may not be the
same and result in mixed data bias. Additionally, in
pooled-data calculation processes, we chose multivariate
data, if they were available. Otherwise, our calculated
data consisted of univariate data without adjusting for
some other influencing factors, such as age, sex, and
histologic grade. This would represent a source of
bias because multivariate studies examine the prognostic
value independently, while univariate studies consider
single factor.
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Conclusion
In spite of all of the limitations and biases of our meta-
analysis, we conclude that long-term use of cetuximab plus
radiation showed no significant difference compared with
cisplatin plus radiation for all of the survival and toxicity
data examined. In subgroup analysis, cetuximab plus radi-
ation may show superior responses regarding OS and PFS
in patients who have HPV+ or primary oropharyngeal
HNSCC, respectively, but physicians should administer
them with caution.
This analysis is a combination of current data. Previously,
it was thought that cetuximab could cause fewer side effects
and may be preferable to cisplatin, as they showed similar
survival outcomes. However, we showed that the two regi-
mens caused toxicity without significant differences, while
cisplatin treatments exhibited better survival outcomes.
Thus, with all of the limitations, we recommend further
RCTs to determine the utility of cetuximab in HNSCC,
especially in the oropharyngeal and/or HPV+ specific
subgroups.
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